Introduction to selexipag and overview of its market launch

Selexipag tablets (Selexipag) is a drug specially used to treatpulmonary arterial hypertension (PAH). It promotes the relaxation of pulmonary arteries by activating prostacyclin receptors (IP receptors) in the body, thereby reducing pulmonary artery pressure and pulmonary vascular resistance, effectively improving the patient's blood circulation, alleviating symptoms, delaying disease progression, and reducing the risk of hospitalization due to pulmonary hypertension.

In terms of market availability, Seripag tablets were developed by ActelionActelion (acquired by Johnson & Johnson in 2017). The drug was first launched in the EU and the United States in 2015 under the trade name "UPTRAVI". In 2018, Serepag tablets were officially launched in China under the trade name "Utopia" and successfully entered the National Medical Insurance Category B catalog. It has become the only oral IP receptor agonist in China, providing patients with a new treatment option.

The launch of Serepag tablets marks a major progress in the treatment of pulmonary arterial hypertension. Its unique mechanism of action and significant efficacy make selepag tablets widely used in clinical practice. At the same time, entering the national medical insurance directory has greatly reduced the financial burden on patients and improved the accessibility of drugs.

It is worth noting that despite the remarkable success of selepag tablets on the market, pulmonary hypertension remains a difficult-to-treat disease. Therefore, patients should pay close attention to their body reactions during medication and conduct relevant examinations regularly so that doctors can adjust treatment plans according to their condition. At the same time, maintaining good living habits and mentality are also important factors in promoting recovery.

To sum up, selepag tablets, as an innovative drug, bring new treatment hope to patients with pulmonary arterial hypertension. Its market launch is going well, providing patients with more treatment options and financial support.

Reference link:https://www.drugs.com/mtm/selexipag-oral-injection.html